Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma

Additional Information

Published Date May 18, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3157
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Lymphoma.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma.

    To find out more about Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part III: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part III: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Actinium Pharmaceuticals
Adherex
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Amgen
Anavex Life Sciences
Antisense Pharma
Antisoma
Apotex
Apricus Biosciences
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bayer
Benitec
Betapharma
Bio-Path Holdings
BioAlliance Pharma
Biocompatibles
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
BioNumerik
BioSante
Bioton
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
Curacyte
CuraGen
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dong-A
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
FasTrack Pharmaceuticals
Favrille
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Gradalis
Green Cross
Hanmi
Hayashibara
Heber Biotec
Heidelberg Pharma
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KaloBios
Kanisa
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Labopharm
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Memgen
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
Noxxon
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
PanaGin
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
POZEN
Pro-Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
ProNAi Therapeutics
Protherics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rigel
Sangamo BioSciences
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Sigma-Tau
Simcere Pharmaceuticals
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
Taxolog
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Vaccinex
Valeant
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viralytics
Wyeth
XBiotech
Xencor
Xerion
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
aflibercept
alemtuzumab
amonafide malate
amrubicin hydrochloride
amsacrine
Angiozyme
barasertib
belinostat
bevacizumab
bexarotene
bisantrene
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
capecitabine
catumaxomab
cediranib
cetuximab
cladribine
clofarabine
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denileukin diftitox
doxifluridine
elacytarabine
elliptinium acetate
enocitabine
enzastaurin hydrochloride
epirubicin
everolimus
galiximab
gemtuzumab ozogamicin
HBP-347
histamine dihydrochloride
ibritumomab tiuxetan
idarubicin
imatinib mesilate
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interferon gamma
irinotecan bead
irinotecan hydrochloride
lestaurtinib
leukemia vaccine
lumiliximab
MGN-1703
midostaurin
mitoxantrone
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
panitumumab
panobinostat
peginterferon alfa-2b
pentostatin
perifosine
pixantrone
pralatrexate
raltitrexed
ramucirumab
razoxane
Reditux
regorafenib
rhIFN-alpha
rituximab
romidepsin
sobuzoxane
tamibarotene
tegafur + uracil
tegafur + uracil + leucovorin
temsirolimus
teniposide
tipifarnib
TS-1
vosaroxin
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma.
    To find out more about Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Leukemia and Lymphoma is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight
With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. Learn More